| Statins for cardiovascular prevention according to different strategies: a cost analysis. | |
| | |
MedLine Citation:
|
PMID: 21265581 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce coronary heart disease (CHD) rates. However, the cost effectiveness of statin treatment in the primary prevention of CHD has not been fully established. Objective: To estimate the costs of CHD prevention using statins in Switzerland according to different guidelines, over a 10-year period. Methods: The overall 10-year costs, costs of one CHD death averted, and of 1 year without CHD were computed for the European Society of Cardiology (ESC), the International Atherosclerosis Society (IAS), and the US Adult Treatment Panel III (ATP-III) guidelines. Sensitivity analysis was performed by varying number of CHD events prevented and costs of treatment. Results: Using an inflation rate of medical costs of 3%, a single yearly consultation, a single total cholesterol measurement per year, and a generic statin, the overall 10-year costs of the ESC, IAS, and ATP-III strategies were 2.2, 3.4, and 4.1 billion Swiss francs (SwF [SwF1 = $US0.97]). In this scenario, the average cost for 1 year of life gained was SwF352, SwF421, and SwF485 thousand, respectively, and it was always higher in women than in men. In men, the average cost for 1 year of life without CHD was SwF30.7, SwF42.5, and SwF51.9 thousand for the ESC, IAS, and ATP-III strategies, respectively, and decreased with age. Statin drug costs represented between 45% and 68% of the overall preventive cost. Changing the cost of statins, inflation rates, or number of fatal and non-fatal cases of CHD averted showed ESC guidelines to be the most cost effective. Conclusion: The cost of CHD prevention using statins depends on the guidelines used. The ESC guidelines appear to yield the lowest costs per year of life gained free of CHD. |
| | |
Authors:
|
Marcia K Ito; David Nanchen; Nicolas Rodondi; Fred Paccaud; Gérard Waeber; Peter Vollenweider; Pedro Marques-Vidal |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 11 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-01-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 33-44 Citation Subset: IM |
Affiliation:
|
Institute of Health Economics and Management (IEMS), University of Lausanne, Lausanne, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The correct administration of antihypertensive drugs according to the principles of clinical pharmac...
Next Document: Dose-Dependent Antihypertensive Efficacy and Tolerability of Perindopril in a Large, Observational, ...